03
Aug
Ayala, Jaeb Center for Wellness Research. == References ==. acuity (VA) 20/50 or worse, VA improvement was greater with aflibercept than the other providers at 12 months, but Meclofenoxate HCl excellent only to bevacizumab at the two year visit. VA remained largely stable from one to two years (aflibercept: 1 . 2 letters [P=0. 24]; bevacizumab: +0. 3 characters [P=0. 85]; ranibizumab: +1. 1 letters [P=0. 40]). Typical letter change in VA over two years (area under curve) was greater with aflibercept (+17. 19. 7) than bevacizumab (+12. 19. 4, P